Drug intelligence / Profile preview

AG23041

Development stage: Unknown
Lead developer: AHN-GOOK PHARMACEUTICAL
Modality: Small Molecules
Administration: Oral

Overview

AG23041 is an investigational small molecule drug developed by Ahn-Gook Pharmaceutical. It is one of the individual components being studied for use in combination with another agent, AG23042, as part of a fixed-dose combination (FDC) product known as AG2304. The primary therapeutic area under investigation for these agents is hypercholesterolemia (primary hypercholesterolemia). The mechanism of action for AG23041 has not been disclosed and remains unknown based on currently available public information. Clinical trials are planned to compare the pharmacokinetics and safety profiles of the FDC (AG2304) versus coadministration of its individual components, including AG23041[2][4][8].

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on AG23041.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG23041.

Explore the full profile